What is the price target for STSA stock?
11 analysts have analysed STSA and the average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1.
Satsuma Pharmaceuticals Inc (STSA) Forecast, Price Target & Analyst Ratings
NASDAQ:STSA • US80405P1075
Current stock price
1.1 USD
-0.01 (-0.9%)
At close:
1.07 USD
-0.03 (-2.73%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Satsuma Pharmaceuticals Inc (STSA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 7, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$0.28
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$2.04
Upside
+ 85.45%
From current price of $1.10 to mean target of $2.04, Based on 11 analyst forecasts
Low
$1.01
Median
$2.04
High
$3.15
Price Target Revisions
1 Month
0.00%
3 Months
-11.11%
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for STSA. The average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1.
The average price target has been revised downward by 11.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.36%
STSA was analyzed by 11 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about STSA.
In the previous month the buy percentage consensus was at a similar level.
STSA was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-04-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | Mizuho | Downgrade | Buy -> Neutral |
| 2022-11-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-10-10 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-09-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-31 | Ladenburg Thalmann | Initiate | Buy |
| 2022-08-25 | JonesTrading | Initiate | Buy |
| 2022-05-13 | Mizuho | Maintains | Buy |
| 2021-06-22 | Mizuho | Upgrade | Neutral -> Buy |
| 2021-05-12 | SVB Leerink | Maintains | Market Perform |
| 2021-03-02 | Credit Suisse | Upgrade | Underperform -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 7, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$0.28
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 46.55%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-10.10%
EPS (3 Months)
-6.45%
Next Earnings Summary
STSA is expected to report earnings on 8/7/2023. The consensus EPS estimate for the next earnings is -0.28 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 293.58% | N/A 37.17% | N/A 51.73% | N/A 10.04% | N/A -20.88% | N/A 10.41% | |||||||
| EBITDA YoY % growth | -4.94M | -7.46M -51.01% | -28.74M -285.25% | -48.09M -67.33% | -50.773M -5.58% | -58.708M -15.63% | N/A 34.24% | N/A 42.54% | N/A 78.62% | N/A 59.14% | N/A 294.74% | N/A 137.84% | N/A 36.36% | N/A 28.33% | |
| EBIT YoY % growth | -4.95M | -7.52M -51.92% | -28.88M -284.04% | -48.33M -67.35% | -51.166M -5.87% | -59.218M -15.74% | N/A 43.09% | N/A 15.65% | N/A -40.41% | N/A 99.29% | N/A 2,216.76% | N/A 228.30% | N/A -39.91% | N/A 18.05% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.74 51.77% | -1.77 35.40% | -2.19 -23.73% | N/A 56.57% | N/A 37.27% | N/A 45.73% | N/A 81.10% | N/A 150.00% | N/A 133.33% | N/A 42.86% | N/A 30.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.28 46.55% | -0.21 55.38% | -0.16 76.69% |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.956M 45.39% | -7.308M 52.57% | -5.968M 49.69% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
22.81%
EPS Next 5 Year
15.03%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
24.32%
EBIT Next 5 Year
15.58%
Satsuma Pharmaceuticals Inc / STSA Forecast FAQ
Can you provide the upcoming earnings date for Satsuma Pharmaceuticals Inc?
Satsuma Pharmaceuticals Inc (STSA) will report earnings on 2023-08-07, after the market close.
What are the consensus estimates for STSA stock next earnings?
The consensus EPS estimate for the next earnings of Satsuma Pharmaceuticals Inc (STSA) is -0.28 USD and the consensus revenue estimate is 0 USD.